Infinity Pharmaceuticals Company Profile (NASDAQ:INFI)

About Infinity Pharmaceuticals (NASDAQ:INFI)

Infinity Pharmaceuticals logoInfinity Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers. The Company is also developing IPI-549, which is an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the gamma isoform of PI3K. In addition to duvelisib, the Company focuses to generate new product candidates for potential investigation in oncology. The Company also focuses on developing DYNAMO, CONTEMPO, BRAVURA, FRESCO, DYNAMO+R, DUO, SYNCHRONY and Duvelisib + Venetoclax.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:INFI
  • CUSIP: 45665G30
  • Web: www.infi.com
Capitalization:
  • Market Cap: $86.76 million
  • Outstanding Shares: 50,443,000
Average Prices:
  • 50 Day Moving Avg: $1.92
  • 200 Day Moving Avg: $2.02
  • 52 Week Range: $0.84 - $5.79
P/E:
  • Trailing P/E Ratio: 860.00
  • Foreward P/E Ratio: -1.21
  • P/E Growth: -0.02
Sales & Book Value:
  • Annual Revenue: $9.47 million
  • Price / Sales: 9.16
  • Book Value: $1.46 per share
  • Price / Book: 1.18
Profitability:
  • EBIDTA: ($88,200,000.00)
  • Net Margins: 13.23%
  • Return on Equity: -125.20%
  • Return on Assets: -54.94%
Debt:
  • Debt-to-Equity Ratio: 0.19%
  • Current Ratio: 4.77%
  • Quick Ratio: 4.77%
Misc:
  • Average Volume: 946,379 shs.
  • Beta: 2.55
  • Short Ratio: 3.05
 

Frequently Asked Questions for Infinity Pharmaceuticals (NASDAQ:INFI)

What is Infinity Pharmaceuticals' stock symbol?

Infinity Pharmaceuticals trades on the NASDAQ under the ticker symbol "INFI."

How were Infinity Pharmaceuticals' earnings last quarter?

Infinity Pharmaceuticals Inc. (NASDAQ:INFI) issued its earnings results on Tuesday, May, 9th. The company reported ($0.21) earnings per share for the quarter, beating analysts' consensus estimates of ($0.22) by $0.01. The firm had revenue of $0.01 million for the quarter, compared to analyst estimates of $19.60 million. Infinity Pharmaceuticals had a net margin of 13.23% and a negative return on equity of 125.20%. The company's quarterly revenue was down 99.9% on a year-over-year basis. During the same quarter last year, the business posted ($0.82) earnings per share. View Infinity Pharmaceuticals' Earnings History.

Where is Infinity Pharmaceuticals' stock going? Where will Infinity Pharmaceuticals' stock price be in 2017?

9 analysts have issued 1 year price objectives for Infinity Pharmaceuticals' shares. Their forecasts range from $1.00 to $2.00. On average, they expect Infinity Pharmaceuticals' stock price to reach $1.60 in the next year. View Analyst Ratings for Infinity Pharmaceuticals.

Are investors shorting Infinity Pharmaceuticals?

Infinity Pharmaceuticals saw a increase in short interest in April. As of April 28th, there was short interest totalling 3,575,706 shares, an increase of 29.3% from the April 13th total of 2,765,545 shares. Based on an average daily trading volume, of 1,048,206 shares, the short-interest ratio is presently 3.4 days. Currently, 7.3% of the shares of the company are sold short.

Who are some of Infinity Pharmaceuticals' key competitors?

Who owns Infinity Pharmaceuticals stock?

Infinity Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (9.32%), Wellington Management Group LLP (9.05%), Renaissance Technologies LLC (2.85%), Pinnacle Associates Ltd. (2.59%), Platinum Investment Management Ltd. (1.61%) and Acadian Asset Management LLC (1.16%). Company insiders that own Infinity Pharmaceuticals stock include Adelene Q Perkins, Michael C Venuti, Sujay Kango, Value Fund L P Biotechnology and Vito J Palombella. View Institutional Ownership Trends for Infinity Pharmaceuticals.

Who sold Infinity Pharmaceuticals stock? Who is selling Infinity Pharmaceuticals stock?

Infinity Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Morgan Stanley, Goldman Sachs Group Inc., TIAA CREF Investment Management LLC, Pinnacle Associates Ltd., Nine Chapters Capital Management LLC, California Public Employees Retirement System and JPMorgan Chase & Co.. Company insiders that have sold Infinity Pharmaceuticals stock in the last year include Michael C Venuti and Sujay Kango. View Insider Buying and Selling for Infinity Pharmaceuticals.

Who bought Infinity Pharmaceuticals stock? Who is buying Infinity Pharmaceuticals stock?

Infinity Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Acadian Asset Management LLC, Dimensional Fund Advisors LP, Platinum Investment Management Ltd., Wellington Management Group LLP, Russell Investments Group Ltd., Citadel Advisors LLC and Nationwide Fund Advisors. View Insider Buying and Selling for Infinity Pharmaceuticals.

How do I buy Infinity Pharmaceuticals stock?

Shares of Infinity Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Infinity Pharmaceuticals stock cost?

One share of Infinity Pharmaceuticals stock can currently be purchased for approximately $1.72.

Analyst Ratings

Consensus Ratings for Infinity Pharmaceuticals (NASDAQ:INFI) (?)
Ratings Breakdown: 9 Hold Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $1.60 (6.98% downside)

Analysts' Ratings History for Infinity Pharmaceuticals (NASDAQ:INFI)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/10/2016JPMorgan Chase & Co.Reiterated RatingHoldN/AView Rating Details
8/11/2016Morgan StanleyReiterated RatingHold$1.00N/AView Rating Details
8/10/2016FBR & CoReiterated RatingHoldN/AView Rating Details
8/9/2016WedbushReiterated RatingNeutral$1.25 -> $1.00N/AView Rating Details
6/15/2016Jefferies Group LLCDowngradeBuy -> HoldN/AView Rating Details
6/15/2016William BlairDowngradeOutperform -> Market Perform$20.00 -> $2.00N/AView Rating Details
6/15/2016Wells Fargo & CoDowngradeOutperform -> Market PerformN/AView Rating Details
6/14/2016Royal Bank of CanadaDowngradeOutperform -> Sector Perform$12.00 -> $2.00N/AView Rating Details
6/14/2016JMP SecuritiesDowngradeOutperform -> Market PerformN/AView Rating Details
(Data available from 5/27/2015 forward)

Earnings

Earnings History for Infinity Pharmaceuticals (NASDAQ:INFI)
Earnings by Quarter for Infinity Pharmaceuticals (NASDAQ:INFI)
Earnings History by Quarter for Infinity Pharmaceuticals (NASDAQ:INFI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($0.22)($0.21)$19.60 million$0.01 millionViewListenView Earnings Details
3/14/2017Q4 2016($0.57)($0.46)$2.33 millionViewN/AView Earnings Details
11/9/2016Q316($0.84)($0.39)$6.23 millionViewListenView Earnings Details
8/9/2016Q216($0.89)$1.05$13.91 million$9.47 millionViewListenView Earnings Details
5/4/2016Q116($0.82)($0.82)$8.80 million$9.26 millionViewListenView Earnings Details
2/23/2016Q415($0.72)($0.80)$18.26 million$9.10 millionViewListenView Earnings Details
11/5/2015Q315($0.76)$0.84$24.85 million$90.70 millionViewN/AView Earnings Details
8/6/2015Q215($1.00)($0.78)$5.83 million$4.90 millionViewN/AView Earnings Details
5/6/2015Q115($1.69)($1.91)$5.79 million$4.40 millionViewListenView Earnings Details
2/24/2015Q414($0.99)($0.83)$5.61 million$4.36 millionViewListenView Earnings Details
11/6/2014Q314($0.87)$2.03$141.40 million$160.60 millionViewListenView Earnings Details
8/5/2014Q114($0.84)($0.78)ViewN/AView Earnings Details
5/6/2014Q1($0.80)($0.87)ViewListenView Earnings Details
2/25/2014Q413($0.87)($0.68)ViewListenView Earnings Details
11/7/2013($0.75)($0.71)ViewN/AView Earnings Details
8/8/2013Q2 2013($0.62)($0.68)ViewListenView Earnings Details
11/6/2012Q312($0.57)$0.52$13.90 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Infinity Pharmaceuticals (NASDAQ:INFI)
2017 EPS Consensus Estimate: ($0.69)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.23)($0.13)($0.18)
Q2 20172($0.21)($0.12)($0.17)
Q3 20172($0.21)($0.13)($0.17)
Q4 20172($0.21)($0.13)($0.17)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Infinity Pharmaceuticals (NASDAQ:INFI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Infinity Pharmaceuticals (NASDAQ:INFI)
Insider Ownership Percentage: 8.20%
Institutional Ownership Percentage: 79.56%
Insider Trades by Quarter for Infinity Pharmaceuticals (NASDAQ:INFI)
Institutional Ownership by Quarter for Infinity Pharmaceuticals (NASDAQ:INFI)
Insider Trades by Quarter for Infinity Pharmaceuticals (NASDAQ:INFI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/17/2017Michael C VenutiDirectorSell6,250$3.48$21,750.00View SEC Filing  
1/3/2017Value Fund L P BiotechnologyMajor ShareholderBuy4,379$1.34$5,867.86View SEC Filing  
12/30/2016Value Fund L P BiotechnologyMajor ShareholderBuy742,401$1.34$994,817.34View SEC Filing  
12/20/2016Value Fund L P BiotechnologyMajor ShareholderBuy654,921$1.31$857,946.51View SEC Filing  
12/13/2016Sujay KangoInsiderSell75,000$1.28$96,000.00View SEC Filing  
12/12/2016Sujay KangoInsiderSell25,009$1.30$32,511.70View SEC Filing  
12/2/2016Value Fund L P BiotechnologyMajor ShareholderBuy201,394$1.19$239,658.86View SEC Filing  
6/25/2015Adelene Q PerkinsCEOSell5,000$10.93$54,650.00View SEC Filing  
6/15/2015Vito J PalombellaInsiderSell4,737$10.97$51,964.89View SEC Filing  
5/27/2015Adelene Q PerkinsCEOSell10,000$12.81$128,100.00View SEC Filing  
5/14/2015Adelene Q PerkinsCEOSell10,000$12.18$121,800.00View SEC Filing  
3/16/2015Adelene Q PerkinsCEOSell20,000$16.00$320,000.00View SEC Filing  
1/29/2015Adelene Q PerkinsCEOSell20,000$14.83$296,600.00View SEC Filing  
12/15/2014Vito J PalombellaInsiderSell4,737$16.32$77,307.84View SEC Filing  
11/26/2014Vito J PalombellaInsiderSell4,736$15.00$71,040.00View SEC Filing  
9/30/2014Anthony B EvninDirectorSell112,451$13.56$1,524,835.56View SEC Filing  
9/3/2014Vito J PalombellaInsiderSell9,472$15.39$145,774.08View SEC Filing  
11/27/2013Anthony B EvninDirectorSell163,864$14.82$2,428,464.48View SEC Filing  
9/13/2013Adelene PerkinsCEOSell45,000$20.72$932,400.00View SEC Filing  
6/20/2013Vito J PalombellaInsiderSell23,150$18.53$428,969.50View SEC Filing  
11/26/2012Christopher M LindblomInsiderSell13,885$25.73$357,261.05View SEC Filing  
9/7/2012Co BeaconMajor ShareholderBuy5,416,565$14.50$78,540,192.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Infinity Pharmaceuticals (NASDAQ:INFI)
Latest Headlines for Infinity Pharmaceuticals (NASDAQ:INFI)
Source:
DateHeadline
americanbankingnews.com logoInfinity Pharmaceuticals Inc. (INFI) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - May 16 at 2:34 PM
americanbankingnews.com logoInfinity Pharmaceuticals Inc. (INFI) Downgraded by Zacks Investment Research
www.americanbankingnews.com - May 16 at 1:34 PM
americanbankingnews.com logoInfinity Pharmaceuticals Inc. (INFI) Expected to Post Earnings of -$0.22 Per Share
www.americanbankingnews.com - May 15 at 10:28 PM
americanbankingnews.com logoInfinity Pharmaceuticals Inc. (INFI) Short Interest Update
www.americanbankingnews.com - May 13 at 7:20 AM
americanbankingnews.com logoQ2 2017 Earnings Forecast for Infinity Pharmaceuticals Inc. (INFI) Issued By William Blair
www.americanbankingnews.com - May 12 at 9:37 AM
businesswire.com logoVerastem Reports First Quarter 2017 Financial Results
www.businesswire.com - May 10 at 6:21 PM
finance.yahoo.com logoEdited Transcript of INFI earnings conference call or presentation 9-May-17 8:30pm GMT
finance.yahoo.com - May 10 at 6:21 PM
prnewswire.com logoInfinity Provides Company Update and Reports First Quarter 2017 ... - PR Newswire (press release)
www.prnewswire.com - May 10 at 1:18 PM
finance.yahoo.com logoInfinity (INFI) Reports Narrower-than-Expected Loss in Q1
finance.yahoo.com - May 10 at 1:18 PM
americanbankingnews.com logoInfinity Pharmaceuticals Inc. (INFI) Posts Earnings Results, Beats Expectations By $0.08 EPS
www.americanbankingnews.com - May 9 at 9:22 PM
marketbeat.com logoInfinity reports 1Q loss
marketbeat.com - May 9 at 5:44 PM
reuters.com logoBRIEF-Infinity reports Q1 loss per share $0.21
www.reuters.com - May 9 at 5:43 PM
finance.yahoo.com logoInfinity Provides Company Update and Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 9 at 5:43 PM
finance.yahoo.com logoInvestor Network: Infinity Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - May 9 at 12:23 PM
finance.yahoo.com logoHorizon (HZNP) Falls on Q1 Earnings Miss, Guidance Trimmed
finance.yahoo.com - May 9 at 12:23 PM
finance.yahoo.com logoCatalent (CTLT) Shows Strength: Stock Adds 9.8% in Session
finance.yahoo.com - May 8 at 7:29 AM
seekingalpha.com logoVerastem Boosts Oncologic Drug Portfolio, Fuels Stock Price
seekingalpha.com - May 7 at 6:18 PM
nasdaq.com logoRegeneron (REGN) Q1 Earnings Miss, Revenues Beat Estimates
www.nasdaq.com - May 4 at 6:05 PM
americanbankingnews.com logoInfinity Pharmaceuticals (INFI) Earning Favorable Media Coverage, Study Finds
www.americanbankingnews.com - May 3 at 10:36 AM
americanbankingnews.com logoInfinity Pharmaceuticals (INFI) Earning Somewhat Favorable Media Coverage, Report Shows
www.americanbankingnews.com - April 27 at 11:50 PM
finance.yahoo.com logoInfinity Announces the Date of Its First Quarter 2017 Financial Results Conference Call and Webcast
finance.yahoo.com - April 26 at 7:26 PM
americanbankingnews.com logoSomewhat Positive News Coverage Very Likely to Affect Infinity Pharmaceuticals (INFI) Share Price
www.americanbankingnews.com - April 21 at 8:09 PM
zacks.com logoAbbVie (ABBV) Presents Positive Data on HCV Combination Drug
www.zacks.com - April 21 at 10:39 AM
finance.yahoo.com logoToday's Research Reports on Biotech Stocks to Watch: Cleveland BioLabs and Infinity Pharmaceuticals - Yahoo Finance
finance.yahoo.com - April 20 at 6:00 PM
finance.yahoo.com logoInfinity Pharmaceuticals (INFI) Looks Good: Stock Jumps 19% - Yahoo Finance
finance.yahoo.com - April 20 at 6:00 PM
finance.yahoo.com logoETFs with exposure to Infinity Pharmaceuticals, Inc. : April 19, 2017
finance.yahoo.com - April 19 at 5:48 PM
finance.yahoo.com logoWhy Is Infinity (INFI) Down 37.4% Since the Last Earnings Report?
finance.yahoo.com - April 19 at 11:25 AM
finance.yahoo.com logoUltragenyx's Hypophosphatemia Drug Succeeds in Phase III
finance.yahoo.com - April 19 at 11:25 AM
americanbankingnews.com logoInfinity Pharmaceuticals (INFI) Earns Coverage Optimism Score of 0.08
www.americanbankingnews.com - April 18 at 2:54 PM
finanznachrichten.de logoGainers & Losers Of Apr.17: CBLI, INFI, PBYI, OMED, INCY...
www.finanznachrichten.de - April 18 at 11:03 AM
finance.yahoo.com logoToday's Research Reports on Biotech Stocks to Watch: Cleveland BioLabs and Infinity Pharmaceuticals
finance.yahoo.com - April 18 at 11:03 AM
finance.yahoo.com logoInfinity Pharmaceuticals (INFI) Looks Good: Stock Jumps 19%
finance.yahoo.com - April 18 at 11:03 AM
finance.yahoo.com logoBio-Path Holdings (BPTH) Looks Good: Stock Moves 13% Higher
finance.yahoo.com - April 17 at 10:50 AM
zacks.com logoNew Strong Buy Stocks for April 10th
www.zacks.com - April 10 at 11:00 AM
finance.yahoo.com logoCardiome Pharma (CRME) Jumps: Stock Adds 6.6% in Session
finance.yahoo.com - April 10 at 11:00 AM
finance.yahoo.com logoInfinity Pharmaceuticals Focuses on Lead Candidate IPI-549
finance.yahoo.com - April 10 at 11:00 AM
finance.yahoo.com logoIncreased Earnings Estimates Seen for Infinity (INFI): Can It Move Higher?
finance.yahoo.com - April 7 at 10:27 AM
finance.yahoo.com logoIsmailia National Food Industries : Neutral assessment on price but strong on fundamentals
finance.yahoo.com - April 7 at 10:27 AM
streetinsider.com logoInfinity Pharma (INFI) Says Updated Phase 1 Data for IPI-549 Presented at AACR - StreetInsider.com
www.streetinsider.com - April 3 at 4:32 PM
finance.yahoo.com logo2:55 am Infinity Pharmaceutical presents updated Phase 1 Data for IPI-549; was well tolerated as a monotherapy and in combination with Opdivo
finance.yahoo.com - April 3 at 4:32 PM
finance.yahoo.com logoUpdated Phase 1 Data for IPI-549 Presented at AACR Annual Meeting 2017
finance.yahoo.com - April 2 at 9:07 AM
biz.yahoo.com logoINFINITY PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements a
biz.yahoo.com - March 29 at 10:34 AM
finance.yahoo.com logoWhat Makes Tesaro (TSRO) a Strong Sell?
finance.yahoo.com - March 29 at 10:34 AM
finance.yahoo.com logoShould You Get Rid of Patheon (PTHN) Now?
finance.yahoo.com - March 29 at 10:34 AM
nasdaq.com logoAre Options Traders Betting on a Big Move in Infinity Pharmaceuticals (INFI) Stock? - Nasdaq
www.nasdaq.com - March 28 at 10:33 PM
finance.yahoo.com logo3 Reasons Why Infinity Pharmaceuticals (INFI) is a Great Momentum Stock
finance.yahoo.com - March 23 at 6:32 PM
finance.yahoo.com logoPieris Pharmaceuticals Reports Full-Year 2016 Financial Results and Corporate Update
finance.yahoo.com - March 22 at 11:07 PM
finance.yahoo.com logoInfinity Pharma Focuses on Cancer Drug: Competition Looms
finance.yahoo.com - March 21 at 5:52 PM
americanbankingnews.com logoInfinity Pharmaceuticals Inc. (INFI) Director Michael C. Venuti Sells 6,250 Shares
www.americanbankingnews.com - March 20 at 8:15 PM
finance.yahoo.com logoINFINITY PHARMACEUTICALS, INC. Financials
finance.yahoo.com - March 18 at 5:21 PM

Social

Chart

Infinity Pharmaceuticals (INFI) Chart for Saturday, May, 27, 2017

This page was last updated on 5/27/2017 by MarketBeat.com Staff